US CDC scientist resigns over Trump admin vaccine data use concerns

Published 16/06/2025, 19:08
© Reuters.

Investing.com -- A senior scientist at the U.S. Centers for Disease Control and Prevention (CDC) resigned Monday, expressing concerns about how COVID-19 and RSV hospitalization data would be used by the Trump administration.

Dr. Fiona Havers, who led the RESP-NET Hospitalization Surveillance Team, told CDC colleagues she no longer had confidence that the data would be used "objectively or evaluated with appropriate scientific rigor to make evidence-based vaccine policy decisions," according to an email viewed by Reuters.

Havers’ resignation comes after Health Secretary Robert Kennedy Jr. fired all 17 members of the CDC’s independent vaccine advisory panel and eliminated recommendations for COVID-19 vaccinations for healthy children and pregnant women.

Kennedy, known for questioning vaccine safety and efficacy, appointed eight new members to the panel, some with histories of opposing COVID-19 vaccines or vaccines generally.

In her email, Havers noted that her team’s COVID and RSV data had contributed to more than 20 peer-reviewed manuscripts and 15 CDC Morbidity and Mortality Weekly Reports.

The newly formed Advisory Committee on Immunization Practices is scheduled to meet June 25-27 to vote on COVID-19 boosters and other vaccines for public use.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.